Cancer Letters
Volume 208, Issue 1 , Pages 51-58 , 10 May 2004

Potentiated anticancer effects on hepatoma cells by the retinoid adapalene

Received 11 July 2003 ,Accepted 22 December 2003.

References 

  1. Figueras J, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A, et al.  Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J. Am. Coll. Surg. 2000;190:580–587
  2. Herold C, Reck T, Fischler P, Ott R, Radespiel-Troeger M, Ganslmayer M, et al.  Prognosis of a large cohort of patients with hepatacellular carcinoma in a single European centre. Liver. 2002;22:23–28
  3. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology. 1998;27:67–72
  4. Minucci S, Pelicci PG. Retinoid receptors in health and disease: co-regulators and the chromatin connection. Semin. Cell Dev. Biol. 1999;10:215–225
  5. Stewart LV, Thomas ML. Retinoids differentially regulate the proliferation of colon cancer cell lines. Exp. Cell Res. 1997;233:321–329
  6. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J. Nutr. 2000;130:479S–482S
  7. Millikan LE. Adapalene: an update on newer comparative studies between the various retinoids. Int. J. Dermatol. 2000;39:784–788
  8. Bershad SV. The modern age of acne therapy: a review of current treatment options. Mt Sinai. J. Med. 2001;68:279–286
  9. Brogden RN, Goa KL. Adapalene. A review of its pharmacological properties and clinical potential in the management of mild to moderate acne. Drugs. 1997;53:511–519
  10. Michel S, Jomard A, Demarchez M. Pharmacology of adapalene. Br. J. Dermatol. 1998;139(Suppl 52):3–7
  11. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J. Am. Acad. Dermatol. 1997;36:96–103
  12. Herold C, Ganslmayer M, Ocker M, Hahn EG, Schuppan D. Combined in vitro anti-tumoral action of tamoxifen and retinoic acid derivatives in hepatoma cells. Int. J. Oncol. 2002;20:89–96
  13. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, et al.  Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. USA. 1991;88:3671–3675
  14. Mancini M, Anderson BO, Caldwell E, Sedghinasab M, Paty PB, Hockenbery DM. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J. Cell. Biol. 1997;138:449–469
  15. Legrand O, Perrot JY, Simonin G, Baudard M, Marie JP. JC-1: a very sensitive fluorescent probe to test Pgp activity in adult myeloid leukemia. Blood. 2001;97:502–508
  16. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, et al.  Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 1999;187:567–572
  17. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, de Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis. 2000;21:1271–1279
  18. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis. 2000;21:525–530
  19. Tallman MS, Wiernik PH. Retinoids in cancer treatment. J. Clin. Pharmacol. 1992;32:868–888
  20. Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ. Retinoids and ovarian cancer. J. Cell Physiol. 2000;185:1–20
  21. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, et al.  Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 1996;334:1561–1567
  22. Falasca L, Marcellini P, Ara C, Rufo A, Devirgiliis LC. Growth inhibition and induction of specific hepatic phenotype expression by retinoic acid in HEPG2 cells. Anticancer Res. 1999;19:3283–3292
  23. Ozeki A, Tsukamoto I. Retinoic acid repressed the expression of c-fos and c-jun and induced apoptosis in regenerating rat liver after partial hepatectomy. Biochim. Biophys. Acta. 1999;1450:308–319
  24. Lamboley C, Bringuier AF, Feldmann G. Induction of apoptosis in normal cultured rat hepatocytes and in Hep3B, a human hepatoma cell line. Cell. Biol. Toxicol. 2000;16:185–200
  25. Li C, Wan YJY. Differentiation and antiproliferation effects of retinoic acid receptor beta in hepatoma cells. Cancer Lett. 1998;124:205–211
  26. Suzui M, Masuda M, Lim JTE, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21cip1 and inhibition of expression of cyclin D1. Cancer Res. 2002;62:3997–4006
  27. Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, et al.  Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J. Hepatol. 2002;36:660–671
  28. Obora A, Shiratori Y, Okuno M, Adachi S, Takano Y, Matsushima-Nishiwaki R, et al.  Synergistic induction of apoptosis by acyclic retinoid and interferon-β in human hepatocellular carcinoma cells. Hepatology. 2002;36:1115–1124
  29. Whitmarsh AJ, Davis RJ. Transcription factor AP-1 regulation by mitogenactivated protein kinase signal transduction pathways. J. Mol. Med. 1996;74:589–607
  30. Curran S, Murray GI. Matrix metalloproteinases: molcular aspects of their roles in tumour invasion and metastasis. Eur. J. Cancer. 2000;36:1621–1630
  31. Monczak Y, Trudel M, Lamph WM, Miller WH. Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. Blood. 1997;90:3345–3355
  32. Suzuki K, Kostin S, Person V, Elsässer A, Schapper J. Time course of the apoptotic cascade and effects of capase inhibitors in adult rat ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 2001;33:983–994
  33. Hengartner MO. The biochemistry of apoptosis. Nature. 2000;407:770–776
  34. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–348
  35. Loeffler M, Kroemer G. The mitochondrion in cell death control: certainties and incognita. Exp. Cell Res. 2000;256:19–26
  36. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al.  Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–730
  37. Antonsson B, Martinou JC. The bcl-2 protein family. Exp. Cell Res. 2000;256:50–57
  38. Belaud-Rotureau MA, Leducq N, Macouillard Poulletier de Gannes F, Diolez P, Lacoste L, Lacombe F, et al.  Early transitory rise in intracellular pH leads to bax conformation change during ceramide-induced apoptosis. Apoptosis. 2000;5:551–560
  39. Rigobello MP, Scutari G, Friso A, Barzon E, Artusi S, Bindoli A. Mitochondrial permeability transition and release of cytochrome c induced by retinoic acids. Biochem. Pharmacol. 1998;58:665–670
  40. Bratton SB, MacFarlane M, Cain K, Cohen GM. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis. Exp. Cell Res. 2000;256:27–33

PII: S0304-3835(04)00057-6

doi: 10.1016/j.canlet.2003.12.026

Cancer Letters
Volume 208, Issue 1 , Pages 51-58 , 10 May 2004

Article Tools

* Image Usage & Resolution